Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aurinia Pharmaceuticals Inc (AUP.TO)

Aurinia Pharmaceuticals Inc (AUP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aurinia Pharmaceuticals Inc 14315 - 118 Avenue Suite 140 Edmonton AB T5L 4S6 CAN

https://www.auriniapharma.com P: 250-708-4272 F: 604-369-4115

Sector:

N/A

INDUSTRY GROUPING:

TSX Indices Health Care

Description:

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Key Statistics

Overview:

Market Capitalization, $K 2,147,902
Shares Outstanding, K 128,396
Annual Sales, $ 235,133 K
Annual Net Income, $ 5,752 K
Last Quarter Sales, $ 73,468 K
Last Quarter Net Income, $ 31,551 K
60-Month Beta 0.26
% of Institutional Shareholders 19.44%

Growth:

1-Year Return -6.73%
3-Year Return 141.50%
5-Year Return 255.84%
5-Year Revenue Growth 274.78%

Per-Share Information:

Next Earnings Date 08/05/21
Earnings Per Share ttm -1.16
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 10/23/13

AUP.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 20.65%
Return-on-Assets % 14.46%
Profit Margin % 2.45%
Debt/Equity 0.17
Price/Sales 32.26
Price/Book 4.67
Book Value/Share 3.59
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar